WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

Firm News

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately held rare disease company, announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Steven Singer and Gary Schall led WilmerHale's representation of Vtesse in this transaction, with a team that included Steven Barrett, William Caporizzo, Jeffrey Hermanson, Scott Kilgore, David Sluis, Libby Ragan, Ben Kelsey and Alan Wilson.

View Vtesse's press release for details.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.